bluuebunny/crossref_metadata_2025 huggingface dataset:
Exploring the Viability of ChatGPT for Personal Data Anonymization in Government: A Comprehensive Analysis of Possibilities, Risks, and Ethical Implications
Authors: van Staalduine Nina , Zuiderwijk Anneke
Published: August 2024

Research on the potential use of ChatGPT for anonymizing texts in government organizations is scarce. This study examines the possibilities, risks, and ethical implications for government organizations to employ ChatGPT in the anonymization of personal data in text documents. It adopts a case study research approach, employing informal conversations, formal interviews, literature review, document analysis, and experiments. The experiments using three types of texts demonstrate ChatGPT's proficiency in anonymizing diverse textual content. Furthermore, the study provides an overview of significant risks and ethical considerations pertinent to ChatGPT's use for text anonymization within government organizations, related to themes such as privacy, responsibility, transparency, bias, human intervention, and sustainability. The current form of ChatGPT stores and forwards inputs to OpenAI and potentially other parties, posing an unacceptable risk when anonymizing texts containing personal data. We discuss several potential solutions to address these risks and ethical issues. This study contributes to the scarce scientific literature on the potential value of employing ChatGPT for text anonymization in government settings. It also offers practical insights for civil servants coping with the challenges of personal data anonymization, emphasizing the need for the cautious consideration of risks and ethical implications in the integration of AI technologies.
Learning-Augmented Energy-Aware List Scheduling for Precedence-Constrained Tasks
Authors: Su Yu , Anand Vivek , Yu Jannie , Tan Jian , Wierman Adam
Published: August 2024

We study the problem of scheduling precedence-constrained tasks to balance between performance and energy consumption. We consider a system with multiple servers capable of speed scaling and seek to schedule precedence-constrained tasks to minimize a linear combination of performance and energy consumption. Inspired by the single-server setting, we propose the concept of
pseudo-size
for individual tasks, which is a measure of the externalities of a task in the precedence graph and is learned from historical workload data. We then propose a two-stage scheduling framework that uses a learned pseudo-size approximation and achieves a provable approximation bound on the linear combination of performance and energy consumption for both makespan and total weighted completion time, where the quality of the bound depends on the approximation quality of pseudo-sizes. We show experimentally that learning-based approaches consistently perform near optimally.
Ecology and Evolution of the Social Microbiome
Authors: Debray Reena , Tung Jenny , Archie Elizabeth A.
Published: August 2024

Animals with close social relationships often have similar microbiomes. These socially structured microbiomes can arise through multiple mechanisms that are often difficult to disentangle, including transmission between social partners or via socially structured, shared environments. Here, we review evidence for socially structured microbiomes and propose methods to differentiate the mechanisms that give rise to them. We discuss the evolutionary implications of these mechanisms for both hosts and their microbiomes, including the possibility that social transmission selects for host-specialized microbiomes. We conclude by identifying outstanding questions related to social microbiomes and their implications for social evolution. We identify new or underutilized approaches like longitudinal study designs, strain-sharing analysis, and culture-based characterization to address these outstanding questions.
Supplementary tables from Estrogen Induces LCAT to Maintain Cholesterol Homeostasis and Suppress Hepatocellular Carcinoma Development
Authors: He Wenzhi , Wang Min , Zhang Xuechun , Wang Yilan , Zhao Dongli , Li Wenhua , Lei Fang , Peng Min , Zhang Zhonglin , Yuan Yufeng , Huang Zan
Published: August 2024

all supplementary tables
Figure S7 from Estrogen Induces LCAT to Maintain Cholesterol Homeostasis and Suppress Hepatocellular Carcinoma Development
Authors: He Wenzhi , Wang Min , Zhang Xuechun , Wang Yilan , Zhao Dongli , Li Wenhua , Lei Fang , Peng Min , Zhang Zhonglin , Yuan Yufeng , Huang Zan
Published: August 2024

Supplementary Figure 7
Figure S6 from Estrogen Induces LCAT to Maintain Cholesterol Homeostasis and Suppress Hepatocellular Carcinoma Development
Authors: He Wenzhi , Wang Min , Zhang Xuechun , Wang Yilan , Zhao Dongli , Li Wenhua , Lei Fang , Peng Min , Zhang Zhonglin , Yuan Yufeng , Huang Zan
Published: August 2024

Supplementary Figure 6
Figure S2 from Estrogen Induces LCAT to Maintain Cholesterol Homeostasis and Suppress Hepatocellular Carcinoma Development
Authors: He Wenzhi , Wang Min , Zhang Xuechun , Wang Yilan , Zhao Dongli , Li Wenhua , Lei Fang , Peng Min , Zhang Zhonglin , Yuan Yufeng , Huang Zan
Published: August 2024

Supplementary Figure 2
Figure S1 from Estrogen Induces LCAT to Maintain Cholesterol Homeostasis and Suppress Hepatocellular Carcinoma Development
Authors: He Wenzhi , Wang Min , Zhang Xuechun , Wang Yilan , Zhao Dongli , Li Wenhua , Lei Fang , Peng Min , Zhang Zhonglin , Yuan Yufeng , Huang Zan
Published: August 2024

Supplementary Figure 1
Table S3 from HDAC Inhibition Increases CXCL12 Secretion to Recruit Natural Killer Cells in Peripheral T-cell Lymphoma
Authors: Zhu Jiayan , Wang Feng , Wang Lining , Dai Bo , Xu Guilin , Zhao Luyao , Jiang Huimin , Gao Wenhui , Zhang Tingting , Zhao Chenxi , Li Yun-Xuan , Hu Jiong , Li Ke
Published: August 2024

Supplementary Table S3. Mass spectrometry analysis identified two acetylation sites of ATF3
Supplementary Figure S6 from HTS384 NCI60: The Next Phase of the NCI60 Screen
Authors: Kunkel Mark W. , Coussens Nathan P. , Morris Joel , Taylor Ronald C. , Dexheimer Thomas S. , Jones Eric M. , Doroshow James H. , Teicher Beverly A.
Published: August 2024

Correlation plots PI3K-targeting agents
Supplementary Video 6 from Human 3D Ovarian Cancer Models Reveal Malignant Cell–Intrinsic and –Extrinsic Factors That Influence CAR T-cell Activity
Authors: Joy Joash D. , Malacrida Beatrice , Laforêts Florian , Kotantaki Panoraia , Maniati Eleni , Manchanda Ranjit , Annibaldi Alessandro , Hopkins Sarah , Garrobo-Calleja Ianire , Gautrot Julien , Balkwill Frances R.
Published: August 2024

Luminal flow of CAR-T cells through vessels formed in the microfluidic device
Supplementary Figure 8 from Human 3D Ovarian Cancer Models Reveal Malignant Cell–Intrinsic and –Extrinsic Factors That Influence CAR T-cell Activity
Authors: Joy Joash D. , Malacrida Beatrice , Laforêts Florian , Kotantaki Panoraia , Maniati Eleni , Manchanda Ranjit , Annibaldi Alessandro , Hopkins Sarah , Garrobo-Calleja Ianire , Gautrot Julien , Balkwill Frances R.
Published: August 2024

Vascularized microfluidic chip to investigate CAR-T cell migration and cytotoxicity.
Supplementary Figure 1 from Human 3D Ovarian Cancer Models Reveal Malignant Cell–Intrinsic and –Extrinsic Factors That Influence CAR T-cell Activity
Authors: Joy Joash D. , Malacrida Beatrice , Laforêts Florian , Kotantaki Panoraia , Maniati Eleni , Manchanda Ranjit , Annibaldi Alessandro , Hopkins Sarah , Garrobo-Calleja Ianire , Gautrot Julien , Balkwill Frances R.
Published: August 2024

OvCAR3 cells were sensitive but G164 cells were resistant to CAR-T cell cytotoxicity in monolayer cultures.
Supplementary Data from Extracellular Vesicles Containing circMYBL1 Induce CD44 in Adenoid Cystic Carcinoma Cells and Pulmonary Endothelial Cells to Promote Lung Metastasis
Authors: Fu Min , Gao Qian , Xiao Mian , Li Rui-Feng , Sun Xin-Yi , Li Sheng-Lin , Peng Xin , Ge Xi-Yuan
Published: August 2024

Supplementary_Methods_and_Figure_Legends
Suppl Table 5 from Extracellular Vesicles Containing circMYBL1 Induce CD44 in Adenoid Cystic Carcinoma Cells and Pulmonary Endothelial Cells to Promote Lung Metastasis
Authors: Fu Min , Gao Qian , Xiao Mian , Li Rui-Feng , Sun Xin-Yi , Li Sheng-Lin , Peng Xin , Ge Xi-Yuan
Published: August 2024

MS for detecting peptide translation
Supp_Tables_S1-S13 from The DNA Methyltransferase Inhibitor 5-Aza-4′-thio-2′-Deoxycytidine Induces C>G Transversions and Acute Lymphoid Leukemia Development
Authors: Bertoli Ryan M. , Chung Yang Jo , Difilippantonio Michael J. , Wokasch Anthony , Marasco Madison R.B. , Klimaszewski Haley , Gammell Susannah , Zhu Yuelin J. , Walker Robert L. , Cao Dengchao , Khanna Ajay , Walter Matthew J. , Doroshow James H. , Meltzer Paul S. , Aplan Peter D.
Published: August 2024

Supp_Tables_S1-S13
Supplementary Figure S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
Authors: Keller Patricia J. , Adams Elizabeth J. , Wu Rentian , Côté Alexandre , Arora Shilpi , Cantone Nico , Meyer Rosana , Mertz Jennifer A. , Gehling Victor , Cui Jike , Stuckey Jacob I. , Khanna Avinash , Zhao Feng , Chen Zehua , Yu Ziyang , Cummings Richard T. , Taimi Mohammed , Lakhani Nehal J. , Rasco Drew , Gutierrez Martin , Duska Linda , Devitt Michael , Rippley Ronda , Levell Julian , Truong Jennifer , Wang Jing , Sun Kaiming , Trojer Patrick
Published: August 2024

Tulmimetostat treatment results in greater PRC2 target gene expression induction in phenotypically sensitive ARID1A LOF cell lines
Supplementary Data from Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer
Authors: Ma Hua , Esfahani Shadi A. , Krishna Shriya , Ataeinia Bahar , Zhou Iris Y. , Rotile Nicholas J. , Weigand-Whittier Jonah , Boice Avery T. , Liss Andrew S. , Tanabe Kenneth K. , Caravan Peter
Published: August 2024

Supplementary method, supplementary figure legends, and references.
Figure S5 from Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer
Authors: Ma Hua , Esfahani Shadi A. , Krishna Shriya , Ataeinia Bahar , Zhou Iris Y. , Rotile Nicholas J. , Weigand-Whittier Jonah , Boice Avery T. , Liss Andrew S. , Tanabe Kenneth K. , Caravan Peter
Published: August 2024

Figure S5. Immediate dynamic contrast enhanced (DCE) MRI in PDAC6 tumor with MnL4 performed before, at 3 days (1 dose FOLFIRNOX), or at 7 days (2 doses FOLFIRINOX) after the initiation of FOLFIRINOX treatment. Time course of change in normalized signal intensity acquired from DCE images with MnL4 as the probe (0.1 mmol/kg, i.v., n = 4 for each group, data shown as mean value with 95% simultaneous confidence bands as shaded regions). Data are superimposable at each time point measured, indicating no changes in tumor permeability or extracellular volume with FOLFIRINOX treatment.
Data from HDAC Inhibition Increases CXCL12 Secretion to Recruit Natural Killer Cells in Peripheral T-cell Lymphoma
Authors: Zhu Jiayan , Wang Feng , Wang Lining , Dai Bo , Xu Guilin , Zhao Luyao , Jiang Huimin , Gao Wenhui , Zhang Tingting , Zhao Chenxi , Li Yun-Xuan , Hu Jiong , Li Ke
Published: August 2024

Abstract
Peripheral T-cell lymphoma (PTCL) is a heterogeneous and aggressive disease with a poor prognosis. Histone deacetylase (HDAC) inhibitors have shown inhibitory effects on PTCL. A better understanding of the therapeutic mechanism underlying the effects of HDAC inhibitors could help improve treatment strategies. Herein, we found that high expression of HDAC3 is associated with poor prognosis in PTCL. HDAC3 inhibition suppressed lymphoma growth in immunocompetent mice but not in immunodeficient mice. HDAC3 deletion delayed the progression of lymphoma, reduced the lymphoma burden in the thymus, spleen, and lymph nodes, and prolonged the survival of mice bearing N-methyl-N-nitrosourea–induced lymphoma. Furthermore, inhibiting HDAC3 promoted the infiltration and enhanced the function of natural killer (NK) cells. Mechanistically, HDAC3 mediated ATF3 deacetylation, enhancing its transcriptional inhibitory activity. Targeting HDAC3 enhanced CXCL12 secretion through an ATF3-dependent pathway to stimulate NK-cell recruitment and activation. Finally, HDAC3 suppression improved the response of PTCL to conventional chemotherapy. Collectively, this study provides insights into the mechanism by which HDAC3 regulates ATF3 activity and CXCL12 secretion, leading to immune infiltration and lymphoma suppression. Combining HDAC3 inhibitors with chemotherapy may be a promising strategy for treating PTCL.

Significance: Targeting HDAC3 suppresses progression of T‐cell lymphoma by activating ATF3 to induce secretion of CXCL12 and promote infiltration of NK cells, providing an immunostimulatory approach for treating T‐cell lymphoma patients.
Data from Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer
Authors: Ma Hua , Esfahani Shadi A. , Krishna Shriya , Ataeinia Bahar , Zhou Iris Y. , Rotile Nicholas J. , Weigand-Whittier Jonah , Boice Avery T. , Liss Andrew S. , Tanabe Kenneth K. , Caravan Peter
Published: August 2024

Abstract
Neoadjuvant therapy is routinely used in pancreatic ductal adenocarcinoma (PDAC), but not all tumors respond to this treatment. Current clinical imaging techniques are not able to precisely evaluate and predict the response to neoadjuvant therapies over several weeks. A strong fibrotic reaction is a hallmark of a positive response, and during fibrogenesis, allysine residues are formed on collagen proteins by the action of lysyl oxidases. Here, we report the application of an allysine-targeted molecular MRI probe, MnL3, to provide an early, noninvasive assessment of treatment response in PDAC. Allysine increased 2- to 3-fold after one dose of neoadjuvant therapy with FOLFIRINOX in sensitive human PDAC xenografts in mice. Molecular MRI with MnL3 could specifically detect and quantify fibrogenesis in PDAC xenografts. Comparing the MnL3 signal before and 3 days after one dose of FOLFIRINOX predicted subsequent treatment response. The MnL3 tumor signal increased by 70% from day 0 to day 3 in mice that responded to subsequent doses of FOLFIRINOX, whereas no signal increase was observed in FOLFIRINOX-resistant tumors. This study indicates the promise of allysine-targeted molecular MRI as a noninvasive tool to predict chemotherapy outcomes.

Significance: Allysine-targeted molecular MRI can quantify fibrogenesis in pancreatic tumors and predict response to chemotherapy, which could guide rapid clinical management decisions by differentiating responders from nonresponders after treatment initiation.
Supplemental Table 4 from Age-Specific Cancer Mortality in the US During the COVID-19 Pandemic, March to December 2020
Authors: Shiels Meredith S. , Haque Anika T. , Freedman Neal D. , Kim Hae-Rin , Berrington de González Amy , Albert Paul S.
Published: August 2024

Supplemental Table 4. Fitted and expected cancer death rates per 1,000 during the COVID-19 period (March-December 2020) by age group.
Supplemental Table 3 from Age-Specific Cancer Mortality in the US During the COVID-19 Pandemic, March to December 2020
Authors: Shiels Meredith S. , Haque Anika T. , Freedman Neal D. , Kim Hae-Rin , Berrington de González Amy , Albert Paul S.
Published: August 2024

Supplemental Table 3. Adjusted rate ratios comparing cancer death rates during the COVID-19 period (March-December 2020) to the pre-COVID-19 period (January 2015-February 2020) age group.
Supplemental Figure 7 from Age-Specific Cancer Mortality in the US During the COVID-19 Pandemic, March to December 2020
Authors: Shiels Meredith S. , Haque Anika T. , Freedman Neal D. , Kim Hae-Rin , Berrington de González Amy , Albert Paul S.
Published: August 2024

Supplemental Figure 7. Adjusted rate ratios comparing prostate cancer death rates during the COVID-19 period (March-December 2020) to the pre-COVID-19 period (January 2011-February 2020) by month by age group. Points represent adjusted rate ratios and lines represent 95% confidence intervals. Models adjusted for linear calendar time in months, and seasonal patterns with sine and cosine terms.
Supplementary table 3 from Understanding Benign Breast Disease and Subsequent Breast Cancer in Hispanic White Females: A Step Closer to Evidence-Based Management
Authors: Lohani Kush R. , Nibbe Andrea M. , Vierkant Robert A. , Pacheco-Spann Laura M. , Seymour Lisa R. , Vachon Celine M. , Sherman Mark E. , Winham Stacey J. , Degnim Amy C. , Hill Deirdre A.
Published: August 2024

Breast cancer cumulative risk in females with atypical hyperplasia adjusted for age and calendar year.
Table S3 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study
Authors: Ruffieux Yann , Fernández Villalobos Nathalie V. , Didden Christiane , Haas Andreas D. , Chinogurei Chido , Cornell Morna , Egger Matthias , Maartens Gary , Folb Naomi , Rohner Eliane
Published: August 2024

Table S3 shows the median prostate specific antigen (PSA) levels in men with and without HIV.
Supplementary Materials from Mammographic Texture versus Conventional Cumulus Measure of Density in Breast Cancer Risk Prediction: A Literature Review
Authors: Ye Zhoufeng , Nguyen Tuong L. , Dite Gillian S. , MacInnis Robert J. , Hopper John L. , Li Shuai
Published: August 2024

Supplementary Materials give a detailed introduction to various types of textural features, the anatomy of the breast, and how mammography works.
Supplemental Table S4 from Rural–Urban Cancer Incidence and Trends in the United States, 2000 to 2019
Authors: Semprini Jason , Gadag Khyathi , Williams Gawain , Muldrow Aniyah , Zahnd Whitney E.
Published: August 2024

Supplemental Table S4: Age-adjusted invasive cancer incidence rates and corresponding 95% confidence intervals per 100,000 by primary site and race/ethnicity and rural status, 2015 to 2019 
Supplementary Figure 3 from Joint Associations of Diet and Device-Measured Physical Activity with Mortality and Incident CVD and Cancer: A Prospective Analysis of the UK Biobank Study
Authors: Inan-Eroglu Elif , Ahmadi Matthew , Biswas Raaj Kishore , Ding Ding , Rezende Leandro F.M. , Lee I-Min , Giovannucci Edward L. , Stamatakis Emmanuel
Published: August 2024

Joint association between physical activity and diet quality score with all-cause mortality and cardiovascular disease, total cancer and physical activity, diet and adiposity related cancer incidence with additional adjustment of total energy intake.Supplementary Figure 3(A-D) shows the joint association between physical activity and diet quality score with all-cause mortality, cardiovascular disease, total cancer, and physical activity, diet, and adiposity-related cancer incidence. This analysis includes additional adjustment for total energy intake and involves a sample size of 58,470 participants.
Supplementary Figure 1. from Joint Associations of Diet and Device-Measured Physical Activity with Mortality and Incident CVD and Cancer: A Prospective Analysis of the UK Biobank Study
Authors: Inan-Eroglu Elif , Ahmadi Matthew , Biswas Raaj Kishore , Ding Ding , Rezende Leandro F.M. , Lee I-Min , Giovannucci Edward L. , Stamatakis Emmanuel
Published: August 2024

Flow chart of the participants Supplementary Figure 1 shows the flow chart of the participants.
Data from Mammographic Texture versus Conventional Cumulus Measure of Density in Breast Cancer Risk Prediction: A Literature Review
Authors: Ye Zhoufeng , Nguyen Tuong L. , Dite Gillian S. , MacInnis Robert J. , Hopper John L. , Li Shuai
Published: August 2024

Abstract
Mammographic textures show promise as breast cancer risk predictors, distinct from mammographic density. Yet, there is a lack of comprehensive evidence to determine the relative strengths as risk predictor of textures and density and the reliability of texture-based measures. We searched the PubMed database for research published up to November 2023, which assessed breast cancer risk associations [odds ratios (OR)] with texture-based measures and percent mammographic density (PMD), and their discrimination [area under the receiver operating characteristics curve (AUC)], using same datasets. Of 11 publications, for textures, six found stronger associations (P < 0.05) with 11% to 508% increases on the log scale by study, and four found weaker associations (P < 0.05) with 14% to 100% decreases, compared with PMD. Risk associations remained significant when fitting textures and PMD together. Eleven of 17 publications found greater AUCs for textures than PMD (P < 0.05); increases were 0.04 to 0.25 by study. Discrimination from PMD and these textures jointly was significantly higher than from PMD alone (P < 0.05). Therefore, different textures could capture distinct breast cancer risk information, partially independent of mammographic density, suggesting their joint role in breast cancer risk prediction. Some textures could outperform mammographic density for predicting breast cancer risk. However, obtaining reliable texture-based measures necessitates addressing various issues. Collaboration of researchers from diverse fields could be beneficial for advancing this complex field.
Supplementary Fig. S7 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Authors: Embaby Alaa , Huijberts Sanne C.F.A. , Wang Liqin , Leite de Oliveira Rodrigo , Rosing Hilde , Nuijen Bastiaan , Sanders Joyce , Hofland Ingrid , van Steenis Charlaine , Kluin Roelof J.C. , Lieftink Cor , Smith Christopher G. , Blank Christian U. , van Thienen Johannes V. , Haanen John B.A.G. , Steeghs Neeltje , Opdam Frans L. , Beijnen Jos H. , Huitema Alwin D.R. , Bernards Rene , Schellens Jan H.M. , Wilgenhof Sofie
Published: August 2024

Supplementary Figure S7. Secondary mutations detected in ctDNA.
Supplementary Fig. S5 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Authors: Embaby Alaa , Huijberts Sanne C.F.A. , Wang Liqin , Leite de Oliveira Rodrigo , Rosing Hilde , Nuijen Bastiaan , Sanders Joyce , Hofland Ingrid , van Steenis Charlaine , Kluin Roelof J.C. , Lieftink Cor , Smith Christopher G. , Blank Christian U. , van Thienen Johannes V. , Haanen John B.A.G. , Steeghs Neeltje , Opdam Frans L. , Beijnen Jos H. , Huitema Alwin D.R. , Bernards Rene , Schellens Jan H.M. , Wilgenhof Sofie
Published: August 2024

Supplementary Fig. S5. The set of eight genes from the MPAS signature was highly enriched in a GSEA analysis using as input the list of genes sorted on the results from the differential analysis “on treatment” vs. “baseline.”
Supplementary Fig. S1 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Authors: Embaby Alaa , Huijberts Sanne C.F.A. , Wang Liqin , Leite de Oliveira Rodrigo , Rosing Hilde , Nuijen Bastiaan , Sanders Joyce , Hofland Ingrid , van Steenis Charlaine , Kluin Roelof J.C. , Lieftink Cor , Smith Christopher G. , Blank Christian U. , van Thienen Johannes V. , Haanen John B.A.G. , Steeghs Neeltje , Opdam Frans L. , Beijnen Jos H. , Huitema Alwin D.R. , Bernards Rene , Schellens Jan H.M. , Wilgenhof Sofie
Published: August 2024

Supplementary Fig. S1. Spider plot showing the best response and change in size of progressive target lesions per patient during treatment.
Supplementary Table S6 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Authors: Tran Duc , Beeler J. Scott , Liu Jie , Wiley Brian , Chan Irenaeus C.C. , Xin Zilan , Kramer Michael H. , Batchi-Bouyou Armel L. , Zong Xiaoyu , Walter Matthew J. , Petrone Giulia E.M. , Chlamydas Sarantis , Ferraro Francesca , Oh Stephen T. , Link Daniel C. , Busby Ben , Cao Yin , Bolton Kelly L.
Published: August 2024

Association between plasma protein levels and clonal hematopoiesis (CH) stratified by VAF.
Supplementary Table S3 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Authors: Tran Duc , Beeler J. Scott , Liu Jie , Wiley Brian , Chan Irenaeus C.C. , Xin Zilan , Kramer Michael H. , Batchi-Bouyou Armel L. , Zong Xiaoyu , Walter Matthew J. , Petrone Giulia E.M. , Chlamydas Sarantis , Ferraro Francesca , Oh Stephen T. , Link Daniel C. , Busby Ben , Cao Yin , Bolton Kelly L.
Published: August 2024

Significantly enriched Reactome gene sets after multiple hypothesis testing correction (pFDR <= 0.05).
Supplementary Table S10 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Authors: Tran Duc , Beeler J. Scott , Liu Jie , Wiley Brian , Chan Irenaeus C.C. , Xin Zilan , Kramer Michael H. , Batchi-Bouyou Armel L. , Zong Xiaoyu , Walter Matthew J. , Petrone Giulia E.M. , Chlamydas Sarantis , Ferraro Francesca , Oh Stephen T. , Link Daniel C. , Busby Ben , Cao Yin , Bolton Kelly L.
Published: August 2024

Asociation between polygenic risk score and risk of myeloid neoplasm (MN) with and without adjusting for CH.
Supplementary Figure S7 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Authors: Tran Duc , Beeler J. Scott , Liu Jie , Wiley Brian , Chan Irenaeus C.C. , Xin Zilan , Kramer Michael H. , Batchi-Bouyou Armel L. , Zong Xiaoyu , Walter Matthew J. , Petrone Giulia E.M. , Chlamydas Sarantis , Ferraro Francesca , Oh Stephen T. , Link Daniel C. , Busby Ben , Cao Yin , Bolton Kelly L.
Published: August 2024

Prediction of MN risk using clinical, CH, and proteomics data.
Supplementary Figure S3 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Authors: Tran Duc , Beeler J. Scott , Liu Jie , Wiley Brian , Chan Irenaeus C.C. , Xin Zilan , Kramer Michael H. , Batchi-Bouyou Armel L. , Zong Xiaoyu , Walter Matthew J. , Petrone Giulia E.M. , Chlamydas Sarantis , Ferraro Francesca , Oh Stephen T. , Link Daniel C. , Busby Ben , Cao Yin , Bolton Kelly L.
Published: August 2024

Association between MN, CH and plasma protein levels.
Supplementary Figure S1 from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Authors: Schmidt Iris , Zhao Xiaojuan , van der Waaij Anne M. , Meersma Gert Jan , Dijkstra Frederieke A. , Haveman Jan Willem , van Etten Boudewijn , Robinson Dominic J. , Kats-Ugurlu Gursah , Nagengast Wouter B.
Published: August 2024

Overview of patient inclusion
Supplementary Table 1 from Mapping the Single-Cell Differentiation Landscape of Osteosarcoma
Authors: Truong Danh D. , Weistuch Corey , Murgas Kevin A. , Admane Prasad , King Bridgette L. , Chauviere Lee Jes , Lamhamedi-Cherradi Salah-E. , Swaminathan Jyothishmathi , Daw Najat C. , Gordon Nancy , Gopalakrishnan Vidya , Gorlick Richard G. , Somaiah Neeta , Deasy Joseph O. , Mikos Antonios G. , Tannenbaum Allen , Ludwig Joseph
Published: August 2024

PDX Clinical Information
Supplementary Figures 1 from Mapping the Single-Cell Differentiation Landscape of Osteosarcoma
Authors: Truong Danh D. , Weistuch Corey , Murgas Kevin A. , Admane Prasad , King Bridgette L. , Chauviere Lee Jes , Lamhamedi-Cherradi Salah-E. , Swaminathan Jyothishmathi , Daw Najat C. , Gordon Nancy , Gopalakrishnan Vidya , Gorlick Richard G. , Somaiah Neeta , Deasy Joseph O. , Mikos Antonios G. , Tannenbaum Allen , Ludwig Joseph
Published: August 2024

Document containing supplementary figures
Supplementary Methods S1 from Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models
Authors: Jain Sonia , Griffith Jessica I. , Porath Kendra A. , Rathi Sneha , Le Jiayan , Pasa Tugce I. , Decker Paul A. , Gupta Shiv K. , Hu Zeng , Carlson Brett L. , Bakken Katrina , Burgenske Danielle M. , Feldsien Thomas M. , Lefebvre Didier R. , Vaubel Rachael A. , Eckel-Passow Jeanette E. , Reilly Edward B. , Elmquist William F. , Sarkaria Jann N.
Published: August 2024

Supplementary data with detailed methods
Supplementary Figure S3 from Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models
Authors: Jain Sonia , Griffith Jessica I. , Porath Kendra A. , Rathi Sneha , Le Jiayan , Pasa Tugce I. , Decker Paul A. , Gupta Shiv K. , Hu Zeng , Carlson Brett L. , Bakken Katrina , Burgenske Danielle M. , Feldsien Thomas M. , Lefebvre Didier R. , Vaubel Rachael A. , Eckel-Passow Jeanette E. , Reilly Edward B. , Elmquist William F. , Sarkaria Jann N.
Published: August 2024

Intracranial tumor growth of GBM39 and GBM6
Supplementary Figure S8 from A 5-Hydroxymethylcytosine-Based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: The METHOD-2 Study
Authors: Chang Wenju , Zhang Zhou , Jia Baoqing , Ding Kefeng , Pan Zhizhong , Su Guoqiang , Zhang Wei , Liu Tianyu , Zhong Yunshi , He Guodong , Ren Li , Wei Ye , Li Dongdong , Cui Xiaolong , Yang Jun , Shi Yixiang , Bissonnette Marc , He Chuan , Zhang Wei , Fan Jia , Xu Jianmin
Published: August 2024

The 5hmC diagnostic model shows cancer type specificity.
Supplementary Figure S5 from Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting
Authors: Ventin Marco , Cattaneo Giulia , Arya Shahrzad , Jia Jingyu , Gelmi Maria C. , Sun Yi , Maggs Luke , Ksander Bruce R. , Verdijk Robert M. , Boland Genevieve M. , Jenkins Russell W. , Haq Rizwan , Jager Martine J. , Wang Xinhui , Ryeom Sandra , Ferrone Cristina R.
Published: August 2024

Supplementary Figure S5. Phenotype of circulating immune cells in humanized mice.
Supplementary Figure S3 from Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting
Authors: Ventin Marco , Cattaneo Giulia , Arya Shahrzad , Jia Jingyu , Gelmi Maria C. , Sun Yi , Maggs Luke , Ksander Bruce R. , Verdijk Robert M. , Boland Genevieve M. , Jenkins Russell W. , Haq Rizwan , Jager Martine J. , Wang Xinhui , Ryeom Sandra , Ferrone Cristina R.
Published: August 2024

Supplementary Figure S3. In vitro and in vivo functionality of the iCas9-based safety switch with B7-H3 CAR T cells.
Supplementary Figure S1 from Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting
Authors: Ventin Marco , Cattaneo Giulia , Arya Shahrzad , Jia Jingyu , Gelmi Maria C. , Sun Yi , Maggs Luke , Ksander Bruce R. , Verdijk Robert M. , Boland Genevieve M. , Jenkins Russell W. , Haq Rizwan , Jager Martine J. , Wang Xinhui , Ryeom Sandra , Ferrone Cristina R.
Published: August 2024

Supplementary Figure S1. Association between B7-H3 mRNA expression and overall survival in patients with UM.
Figure S2 from Exposure–Response and Subgroup Analyses to Support Body Weight–Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin Lymphoma
Authors: Zhang Zufei , Zhang Daping , Guo Wenchuan , Fenton Keenan , Narayanan Sujata , Jain Shweta , Jiang Joy , Castellino Sharon M. , Kelly Kara M. , Cole Peter D. , Keller Frank G. , Garg Amit , Chia Yen Lin
Published: August 2024

Mean concentration-time curves for ADC and MMAE during Cycle 4 following intravenous administration of brentuximab vedotin in the PK subpopulation.
Supplementary Table S4 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Authors: Pankova Valeriya , Krasny Lukas , Kerrison William , Tam Yuen B. , Chadha Madhumeeta , Burns Jessica , Wilding Christopher P. , Chen Liang , Chowdhury Avirup , Perkins Emma , Lee Alexander T.J. , Howell Louise , Guljar Nafia , Sisley Karen , Fisher Cyril , Chudasama Priya , Thway Khin , Jones Robin L. , Huang Paul H.
Published: August 2024

Supplementary Table S4: Statistical comparisons between histological subtypes in cluster 1 (C1).
Supplementary Table S12 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Authors: Pankova Valeriya , Krasny Lukas , Kerrison William , Tam Yuen B. , Chadha Madhumeeta , Burns Jessica , Wilding Christopher P. , Chen Liang , Chowdhury Avirup , Perkins Emma , Lee Alexander T.J. , Howell Louise , Guljar Nafia , Sisley Karen , Fisher Cyril , Chudasama Priya , Thway Khin , Jones Robin L. , Huang Paul H.
Published: August 2024

Supplementary Table S12. Summary of univariable (UVA) and multivariable (MVA) Cox regression analyses assessing the association of clinicopathological factors and median proteoglycan score with overall survival (OS).
Supplementary Table S1 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Authors: Pankova Valeriya , Krasny Lukas , Kerrison William , Tam Yuen B. , Chadha Madhumeeta , Burns Jessica , Wilding Christopher P. , Chen Liang , Chowdhury Avirup , Perkins Emma , Lee Alexander T.J. , Howell Louise , Guljar Nafia , Sisley Karen , Fisher Cyril , Chudasama Priya , Thway Khin , Jones Robin L. , Huang Paul H.
Published: August 2024

Supplementary Table S1: Matrisome and adhesome proteins identified across the soft tissue sarcoma (STS) cohort. Table showing annotation of proteins according to matrisome and integrin adhesome databases and the breakdown into functional matrisome and adhesome categories.
Supplementary Methods S1 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Authors: Pankova Valeriya , Krasny Lukas , Kerrison William , Tam Yuen B. , Chadha Madhumeeta , Burns Jessica , Wilding Christopher P. , Chen Liang , Chowdhury Avirup , Perkins Emma , Lee Alexander T.J. , Howell Louise , Guljar Nafia , Sisley Karen , Fisher Cyril , Chudasama Priya , Thway Khin , Jones Robin L. , Huang Paul H.
Published: August 2024

Supplemental Methods
Supplementary Table S3 from A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma
Authors: Chang Elaine , Zhou Jiaxi , Song Chi , Gittleman Haley , Fernandes Laura , Weinstock Chana , Atkins Michael B. , Agrawal Sundeep , Sridhara Rajeshwari , Gormley Nicole , Tang Shenghui , Suzman Daniel L. , Amiri-Kordestani Laleh , Kluetz Paul G. , Pazdur Richard , Rini Brian I. , McDermott David F. , Regan Meredith M.
Published: August 2024

Time on Each Drug as Monotherapy in IO-TKI Combination
Data from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Authors: Embaby Alaa , Huijberts Sanne C.F.A. , Wang Liqin , Leite de Oliveira Rodrigo , Rosing Hilde , Nuijen Bastiaan , Sanders Joyce , Hofland Ingrid , van Steenis Charlaine , Kluin Roelof J.C. , Lieftink Cor , Smith Christopher G. , Blank Christian U. , van Thienen Johannes V. , Haanen John B.A.G. , Steeghs Neeltje , Opdam Frans L. , Beijnen Jos H. , Huitema Alwin D.R. , Bernards Rene , Schellens Jan H.M. , Wilgenhof Sofie
Published: August 2024

AbstractPurpose:
The development of resistance limits the clinical benefit of BRAF and MEK inhibitors (BRAFi/MEKi) in BRAFV600-mutated melanoma. It has been shown that short-term treatment (14 days) with vorinostat was able to initiate apoptosis of resistant tumor cells. We aimed to assess the antitumor activity of sequential treatment with vorinostat following BRAFi/MEKi in patients with BRAFV600-mutated melanoma who progressed after initial response to BRAFi/MEKi.
Patients and Methods:
Patients with BRAFi/MEKi-resistant BRAFV600-mutated melanoma were treated with vorinostat 360 mg once daily for 14 days followed by BRAFi/MEKi. The primary endpoint was an objective response rate of progressive lesions of at least 30% according to Response Evaluation Criteria in Solid Tumors 1.1. Secondary endpoints included progression-free survival, overall survival, safety, pharmacokinetics of vorinostat, and translational molecular analyses using ctDNA and tumor biopsies.
Results:
Of the 26 patients with progressive BRAFi/MEKi-resistant BRAFV600-mutated melanoma receiving treatment with vorinostat, 22 patients were evaluable for response. The objective response rate was 9%, with one complete response for 31.2 months and one partial response for 14.9 months. Median progression-free survival and overall survival were 1.4 and 5.4 months, respectively. Common adverse events were fatigue (23%) and nausea (19%). ctDNA analysis showed emerging secondary mutations in NRAS and MEK in eight patients at the time of BRAFi/MEKi resistance. Elimination of these mutations by vorinostat treatment was observed in three patients.
Conclusions:
Intermittent treatment with vorinostat in patients with BRAFi/MEKi-resistant BRAFV600-mutated melanoma is well tolerated. Although the primary endpoint of this study was not met, durable antitumor responses were observed in a minority of patients (9%).
Data from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Authors: Tran Duc , Beeler J. Scott , Liu Jie , Wiley Brian , Chan Irenaeus C.C. , Xin Zilan , Kramer Michael H. , Batchi-Bouyou Armel L. , Zong Xiaoyu , Walter Matthew J. , Petrone Giulia E.M. , Chlamydas Sarantis , Ferraro Francesca , Oh Stephen T. , Link Daniel C. , Busby Ben , Cao Yin , Bolton Kelly L.
Published: August 2024

AbstractPurpose:
Clonal hematopoiesis (CH) is thought to be the origin of myeloid neoplasms (MN). Yet, our understanding of the mechanisms driving CH progression to MN and clinical risk prediction of MN remains limited. The human proteome reflects complex interactions between genetic and epigenetic regulation of biological systems. We hypothesized that the plasma proteome might predict MN risk and inform our understanding of the mechanisms promoting MN development.
Experimental Design:
We jointly characterized CH and plasma proteomic profiles of 46,237 individuals in the UK Biobank at baseline study entry. During 500,036 person-years of follow-up, 115 individuals developed MN. Cox proportional hazard regression was used to test for an association between plasma protein levels and MN risk.
Results:
We identified 115 proteins associated with MN risk, of which 30% (N = 34) were also associated with CH. These were enriched for known regulators of the innate and adaptive immune system. Plasma proteomics improved the prediction of MN risk (AUC = 0.85; P = 5×10–9) beyond clinical factors and CH (AUC = 0.80). In an independent group (N = 381,485), we used inherited polygenic risk scores (PRS) for plasma protein levels to validate the relevance of these proteins toMNdevelopment. PRS analyses suggest that most MN-associated proteins we identified are not directly causally linked toMN risk, but rather represent downstream markers of pathways regulating the progression of CH to MN.
Conclusions:
These data highlight the role of immune cell regulation in the progression of CH to MN and the promise of leveraging multi-omic characterization of CH to improveMN risk stratification.

See related commentary by Bhalgat and Taylor, p. 3095
Data from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Authors: Pankova Valeriya , Krasny Lukas , Kerrison William , Tam Yuen B. , Chadha Madhumeeta , Burns Jessica , Wilding Christopher P. , Chen Liang , Chowdhury Avirup , Perkins Emma , Lee Alexander T.J. , Howell Louise , Guljar Nafia , Sisley Karen , Fisher Cyril , Chudasama Priya , Thway Khin , Jones Robin L. , Huang Paul H.
Published: August 2024

AbstractPurpose:
The landscape of extracellular matrix (ECM) alterations in soft tissue sarcomas (STS) remains poorly characterized. We aimed to investigate the tumor ECM and adhesion signaling networks present in STS and their clinical implications.
Experimental Design:
Proteomic and clinical data from 321 patients across 11 histological subtypes were analyzed to define ECM and integrin adhesion networks. Subgroup analysis was performed in leiomyosarcomas (LMS), dedifferentiated liposarcomas (DDLPS), and undifferentiated pleomorphic sarcomas (UPS).
Results:
This analysis defined subtype-specific ECM profiles including enrichment of basement membrane proteins in LMS and ECM proteases in UPS. Across the cohort, we identified three distinct coregulated ECM networks which are associated with tumor malignancy grade and histological subtype. Comparative analysis of LMS cell line and patient proteomic data identified the lymphocyte cytosolic protein 1 cytoskeletal protein as a prognostic factor in LMS. Characterization of ECM network events in DDLPS revealed three subtypes with distinct oncogenic signaling pathways and survival outcomes. Evaluation of the DDLPS subtype with the poorest prognosis nominates ECM remodeling proteins as candidate antistromal therapeutic targets. Finally, we define a proteoglycan signature that is an independent prognostic factor for overall survival in DDLPS and UPS.
Conclusions:
STS comprise heterogeneous ECM signaling networks and matrix-specific features that have utility for risk stratification and therapy selection, which could in future guide precision medicine in these rare cancers.
Data from Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Authors: Nguyen Charles B. , Reimers Melissa A. , Perera Chamila , Abida Wassim , Chou Jonathan , Feng Felix Y. , Antonarakis Emmanuel S. , McKay Rana R. , Pachynski Russell K. , Zhang Jingsong , Reichert Zachery R. , Palmbos Phillip L. , Caram Megan E.V. , Vaishampayan Ulka N. , Heath Elisabeth I. , Hopkins Alexander C. , Cieslik Marcin P. , Wu Yi-Mi , Robinson Dan R. , Baladandayuthapani Veerabhadran , Chinnaiyan Arul M. , Alva Ajjai S.
Published: August 2024

AbstractPurpose:
CDK12 inactivation in metastatic castration-resistant prostate cancer (mCRPC) may predict immunotherapy responses. This phase 2 trial evaluated the efficacy of immune checkpoint inhibitor (ICI) therapy in patients with CDK12-altered mCRPC.
Patients and Methods:
Eligible patients had mCRPC with deleterious CDK12 alterations and any prior therapies except ICI. Cohort A received ipilimumab (1 mg/kg) with nivolumab (3 mg/kg) every 3 weeks for up to four cycles, followed by nivolumab 480 mg every 4 weeks. Cohort C received nivolumab alone 480 mg every 4 weeks. Patients with CDK12-altered nonprostate tumors were enrolled in cohort B and not reported. The primary endpoint was a 50% reduction in PSA (PSA50). Key secondary endpoints included PSA progression-free survival, overall survival, objective response rate, and safety.
Results:
PSA was evaluable in 23 patients in cohort A and 14 in cohort C. Median lines of prior therapy were two in cohorts A and C, including any prior novel hormonal agent (74% and 79%) and chemotherapy (57% and 36%). The PSA50 rate was 9% [95% confidence interval (CI), 1%–28%] in cohort A with two responders; neither had microsatellite instability or a tumor mutational burden >10 mutations/megabase. No PSA50 responses occurred in cohort C. Median PSA progression-free survival was 7.0 months (95% CI, 3.6–11.4) in cohort A and 4.5 months (95% CI, 3.4–13.8) in cohort C. Median overall survival was 9.0 months (95% CI, 6.2–12.3) in cohort A and 13.8 months (95% CI, 3.6–not reached) in cohort C.
Conclusions:
There was minimal activity with ICI therapy in patients with CDK12-altered mCRPC.
Table S3 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
Authors: Kong Ying , Zhao Xinyue , Wang Zhaofu , Yuan Siqi , Chen Sheng , Lou Shidi , Ma Shichao , Li Yunfeng , Wang Xinghao , Ge Yangfeng , Li Guobin , Yang Hongbing , Zhao Mengxi , Li Dandan , Zhang Hailong , Tan Wenfu , Wang Juan
Published: August 2024

Pharmacokinetics parameters for BR-cpd7.
Table S1 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
Authors: Kong Ying , Zhao Xinyue , Wang Zhaofu , Yuan Siqi , Chen Sheng , Lou Shidi , Ma Shichao , Li Yunfeng , Wang Xinghao , Ge Yangfeng , Li Guobin , Yang Hongbing , Zhao Mengxi , Li Dandan , Zhang Hailong , Tan Wenfu , Wang Juan
Published: August 2024

SAR of optimal linker lengths and species in FGFR degraders designed based on BGJ398. Similar to BR-cpd7, Compounds 1-11 were prepared from building block 1 in 3 steps. Including reductive amination of building block 1 with corresponding acetones or aldehydes, deprotection and condensation. HEK293T cells transfected with HiBiT-FGFR1 were treated with FGFR degraders for 36 h. FGFR1 protein level was quantified with Nano-Glo HiBiT (n=3 replicates).
Supplementary Figure S2 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
Authors: Bratti Manuela , Stubbs Elisa , Kolodych Sergii , Souchet Herve , Kelly Lois , Merlin Johanna , Marchal Michelle , Castellano Remy , Josselin Emmanuelle , Pasquer Hélène , Benajiba Lina , Puissant Alexandre , Koniev Oleksandr , Collette Yves , Belanger Coralie , Hermine Olivier , Monteiro Renato C. , Launay Pierre
Published: August 2024

Figure S2
Supplemental Figure 6 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0
Authors: Markowitz Joseph , Shamblott Michael , Brohl Andrew S. , Sarnaik Amod A. , Eroglu Zeynep , Khushalani Nikhil I. , Dukes Christopher W. , Chamizo Alejandra , Bastawrous Marina , Garcia Edward T. , Dehlawi Ashraf , Chen Pei-Ling , De Aquino Deanryan B. , Sondak Vernon K. , Tarhini Ahmad A. , Kim Youngchul , Lawman Patricia , Pilon-Thomas Shari
Published: August 2024

Supplemental Figure 6: Emm55 specific peptides responsible for IgM responses pre and posttreatment on individual patients.
Supplemental Figure 5 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0
Authors: Markowitz Joseph , Shamblott Michael , Brohl Andrew S. , Sarnaik Amod A. , Eroglu Zeynep , Khushalani Nikhil I. , Dukes Christopher W. , Chamizo Alejandra , Bastawrous Marina , Garcia Edward T. , Dehlawi Ashraf , Chen Pei-Ling , De Aquino Deanryan B. , Sondak Vernon K. , Tarhini Ahmad A. , Kim Youngchul , Lawman Patricia , Pilon-Thomas Shari
Published: August 2024

Emm55 specific peptides responsible for IgG responses pre and post treatment on individual patients.
Supplemental Figure 9 from Blockade of Discoidin Domain Receptor Signaling with Sitravatinib Reveals DDR2 as a Mediator of Neuroblastoma Pathogenesis and Metastasis
Authors: Rozen Esteban J. , Frantz William , Wigglesworth Kim , Vessella Theadora , Zhou Hong S. , Shohet Jason M.
Published: August 2024

Single cell RNA sequencing of neuroblastoma patient samples demonstrates intra and inter tumor heterogeneity of SCP-like cells.
Supplementary Figure S1 from Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window
Authors: Satomaa Tero , Pynnönen Henna , Aitio Olli , Hiltunen Jukka O. , Pitkänen Virve , Lähteenmäki Tuula , Kotiranta Titta , Heiskanen Annamari , Hänninen Anna-Liisa , Niemelä Ritva , Helin Jari , Kuusanmäki Heikki , Vänttinen Ida , Rathod Ramji , Nieminen Anni I. , Yatkin Emrah , Heckman Caroline A. , Kontro Mika , Saarinen Juhani
Published: August 2024

Characterization of LN-mcvc-MMAE DAR4 (lintuzumab vedotin).
Supplemental Figure 1 from Blockade of Discoidin Domain Receptor Signaling with Sitravatinib Reveals DDR2 as a Mediator of Neuroblastoma Pathogenesis and Metastasis
Authors: Rozen Esteban J. , Frantz William , Wigglesworth Kim , Vessella Theadora , Zhou Hong S. , Shohet Jason M.
Published: August 2024

Chemical structure of sitravatinib
Figure S6 from TNIK Inhibition Sensitizes TNIK-Overexpressing Lung Squamous Cell Carcinoma to Radiotherapy
Authors: Nguyen Triet , Carrieri Francesca A. , Connis Nick , Lafargue Audrey , Chang Jinhee , Chan Aaron , Shetty Amol C. , Song Yang , Hoang Tung , Jagtap Shreya , Chowdhury Dipanwita D. , Khan Muhammad A. , Gabrielson Kathleen L. , Rezaee Mohammad , Torres-Ayuso Pedro , Brognard John , Hann Christine L. , Tran Phuoc T.
Published: August 2024

TNIK inhibition disrupted the DDR in a TNIK-specific fashion.
Figure S3 from TNIK Inhibition Sensitizes TNIK-Overexpressing Lung Squamous Cell Carcinoma to Radiotherapy
Authors: Nguyen Triet , Carrieri Francesca A. , Connis Nick , Lafargue Audrey , Chang Jinhee , Chan Aaron , Shetty Amol C. , Song Yang , Hoang Tung , Jagtap Shreya , Chowdhury Dipanwita D. , Khan Muhammad A. , Gabrielson Kathleen L. , Rezaee Mohammad , Torres-Ayuso Pedro , Brognard John , Hann Christine L. , Tran Phuoc T.
Published: August 2024

Short-term TNIK inhibition radiosensitized LSCC cells.